L-securinine induces apoptosis in the human promyelocytic leukemia cell line HL-60 and influences the expression of genes involved in the PI3K/AKT/mTOR signaling pathway

Han,Shuwen; Zhang,Gang; Li,Maidong; Chen,Dongyun; Wang,Ying; Ye,Wencai; Ji,Zhaoning

doi:10.3892/or.2014.3101

L-securinine induces apoptosis in the human promyelocytic leukemia cell line HL-60 and influences the expression of genes involved in the PI3K/AKT/mTOR signaling pathway

Authors:
- Shuwen Han
- Gang Zhang
- Maidong Li
- Dongyun Chen
- Ying Wang
- Wencai Ye
- Zhaoning Ji
View Affiliations

Affiliations: Department of Oncology, Wannan Medical College, Wuhu, Anhui, P.R. China, The Cancer Center, Yijishan Hospital of Wannan Medical College, Wuhu, Anhui, P.R. China, Institute of Traditional Chinese Medicine and Natural Products, Jinan University, Guangzhou, P.R. China
Published online on: March 20, 2014 https://doi.org/10.3892/or.2014.3101
Pages: 2245-2251

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The Securinega alkaloids are a class of natural products isolated from plants of the Euphorbiaceae family. L-securinine induces apoptosis in the human promyelocytic leukemia cell line HL-60 indicating its potential as an efficient natural antitumor drug with low toxicity. The aim of the present study was to investigate the apoptotic effects of L-securinine on HL-60 cells and to explore its potential underlying molecular mechanism(s) as an antitumor agent. HL-60 cells were cultured with L-securinine. The proliferation and changes in cell morphology were evaluated by cell counting Kit-8 (CCK-8) assay and electron microscopy, respectively. Induction of apoptosis and cell cycle progression were investigated by flow cytometry. The PI3K/AKT/mTOR pathway gene expression was measured by quantitative PCR (qPCR). L-securinine decreased the viability of HL-60 cells in a dose- and time-dependent manner, with IC50 values at 24, 48 and 72 h post-treatment of 47.88, 23.85 and 18.87 µmol/l, respectively. Numerous apoptotic bodies were observed in the HL-60 cells treated with 25 µmol/l L-securinine for 48 h. L-securinine at 12.5, 25 and 50 µmol/l increased the rate of apoptosis in HL-60 cells, and G1/S phase progression was retarded. Furthermore, L-securinine induced downregulation of PI3K, AKT and mTOR gene expression and upregulation of PTEN gene expression in a dose-dependent manner. In conclusion, L-securinine induces apoptosis and inhibition of cell cycle progression in HL-60 cells by modulation of the PI3K/AKT/mTOR pathway gene expression. These observations indicate the potential of L-securinine as an antitumor agent.

View Figures

View References

1	Pui CH: Recent research advances in childhood acute lymphoblastic leukemia. J Formos Med Assoc. 109:777–787. 2010. View Article : Google Scholar : PubMed/NCBI
2	Kaspers GJ and Creutzig U: Pediatric acute myeloid leukemia: international progress and future directions. Leukemia. 19:2025–2029. 2005. View Article : Google Scholar
3	Kim KC, Kim JS, Son JK and Kim IG: Enhanced induction of mitochondrial damage and apoptosis in human leukemia HL-60 cells by the Ganoderma lucidum and Duchesnea chrysantha extracts. Cancer Lett. 246:210–217. 2007. View Article : Google Scholar : PubMed/NCBI
4	Muraveva V and Bankovskii A: Chemical study of alkaloids of Securinega suffruticosa. Doklady Akad Nauk SSSR. 110:998–1000. 1956.
5	Saito S, Kotera K, Shigematsu N, Ide A, Sugimoto N, Horii Z, Hanaoka M, Yamawaki Y and Tamura Y: Structure of securinine. Tetrahedron. 19:2085–2099. 1963. View Article : Google Scholar : PubMed/NCBI
6	Imado S, Shiro M and Horii Z: The crystal structure of securinine hydrobromide dihydrate and the molecular structure of securinine. Chem Pharm Bull. 13:643–651. 1965. View Article : Google Scholar
7	Peng JZ: Securinine pharmacological and clinical progress. J Ningxia Med Coll. 16:21994.
8	Beutler JA, Karbon EW, Brubaker AN, Malik R, Curtis DR and Enna SJ: Securinine alkaloids: a new class of GABA receptor antagonist. Brain Res. 330:135–140. 1985. View Article : Google Scholar : PubMed/NCBI
9	CL Y, LQ L and LS S: The treatment of aplastic anemia. Tianjin Med J. 9:662–665. 1981.
10	Weenen H, Nkunya MH, Bray DH, Mwasumbi LB, Kinabo LS, Kilimali VA and Wijnberg JB: Antimalarial compounds containing an α, β-unsaturated carbonyl moiety from Tanzanian medicinal plants. Planta Med. 56:371–373. 1990.
11	Mensah JL, Lagarde I, Ceschin C, Michel G, Gleye J and Fouraste I: Antibacterial activity of the leaves of Phyllanthus discoideus. J Ethnopharmacol. 28:129–133. 1990. View Article : Google Scholar : PubMed/NCBI
12	Chen CR, Xia YH, Yao SY, Zhang Q, Wang Y and Ji ZN: Virosecurinine induces apoptosis by affecting Bcl-2 and Bax expression in human colon cancer SW480 cells. Pharmazie. 67:351–354. 2012.PubMed/NCBI
13	Carnero A, Blanco-Aparicio C, Renner O, Link W and Leal JF: The PTEN/PI3K/AKT signalling pathway in cancer, therapeutic implications. Curr Cancer Drug Targets. 8:187–198. 2008. View Article : Google Scholar : PubMed/NCBI
14	Burnett PE, Barrow RK, Cohen NA, Snyder SH and Sabatini DM: RAFT1 phosphorylation of the translational regulators p70 S6 kinase and 4E-BP1. Proc Natl Acad Sci USA. 95:1432–1437. 1998. View Article : Google Scholar
15	West KA, Linnoila IR, Belinsky SA, Harris CC and Dennis PA: Tobacco carcinogen-induced cellular transformation increases activation of the phosphatidylinositol 3′-kinase/Akt pathway in vitro and in vivo. Cancer Res. 64:446–451. 2004.PubMed/NCBI
16	Janku F, Stewart DJ and Kurzrock R: Targeted therapy in non-small-cell lung cancer - is it becoming a reality? Nat Rev Clin Oncol. 7:401–414. 2010. View Article : Google Scholar : PubMed/NCBI
17	Reungwetwattana T, Weroha SJ and Molina JR: Oncogenic pathways, molecularly targeted therapies, and highlighted clinical trials in non-small-cell lung cancer (NSCLC). Clin Lung Cancer. 13:252–266. 2012. View Article : Google Scholar : PubMed/NCBI
18	Hay N and Sonenberg N: Upstream and downstream of mTOR. Genes Dev. 18:1926–1945. 2004. View Article : Google Scholar
19	Ozpolat B, Akar U, Steiner M, Zorrilla-Calancha I, Tirado-Gomez M, Colburn N, Danilenko M, Kornblau S and Berestein GL: Programmed cell death-4 tumor suppressor protein contributes to retinoic acid-induced terminal granulocytic differentiation of human myeloid leukemia cells. Mol Cancer Res. 5:95–108. 2007. View Article : Google Scholar
20	Hudes G, Carducci M, Tomczak P, Dutcher J, Figlin R, Kapoor A, Staroslawska E, Sosman J, McDermott D, Bodrogi I, Kovacevic Z, Lesovoy V, Schmidt-Wolf IG, Barbarash O, Gokmen E, O’Toole T, Lustgarten S, Moore L, Motzer RJ and Global AT: Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma. N Engl J Med. 356:2271–2281. 2007. View Article : Google Scholar
21	Yao JC, Shah MH, Ito T, Bohas CL, Wolin EM, Van Cutsem E, Hobday TJ, Okusaka T, Capdevila J, de Vries EG, Tomassetti P, Pavel ME, Hoosen S, Haas T, Lincy J, Lebwohl D and Oberg K; RAD001 in Advanced Neuroendocrine Tumors, Third Trial (RADIANT-3) Study Group. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 364:514–523. 2011. View Article : Google Scholar : PubMed/NCBI
22	Baselga J, Campone M, Piccart M, Burris HA III, Rugo HS, Sahmoud T, Noguchi S, Gnant M, Pritchard KI, Lebrun F, Beck JT, Ito Y, Yardley D, Deleu I, Perez A, Bachelot T, Vittori L, Xu Z, Mukhopadhyay P, Lebwohl D and Hortobagyi GN: Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med. 366:520–529. 2012. View Article : Google Scholar : PubMed/NCBI
23	Maiuri MC, Tasdemir E, Criollo A, Morselli E, Vicencio JM, Carnuccio R and Kroemer G: Control of autophagy by oncogenes and tumor suppressor genes. Cell Death Differ. 16:87–93. 2009. View Article : Google Scholar : PubMed/NCBI
24	Huang FF, Wu DS, Zhang L, Yu YH, Yuan XY, Li WJ, Chen XP, Zhao XL, Chen FP and Zeng H: Inactivation of PTEN increases ABCG2 expression and the side population through the PI3K/Akt pathway in adult acute leukemia. Cancer Lett. 336:96–105. 2013. View Article : Google Scholar : PubMed/NCBI
25	Inayat-Hussain SH, Osman AB, Din LB and Taniguchi N: Altholactone, a novel styryl-lactone induces apoptosis via oxidative stress in human HL-60 leukemia cells. Toxicol Lett. 131:153–159. 2002. View Article : Google Scholar : PubMed/NCBI
26	Pelicano H, Feng L, Zhou Y, Carew JS, Hileman EO, Plunkett W, Keating MJ and Huang P: Inhibition of mitochondrial respiration: a novel strategy to enhance drug-induced apoptosis in human leukemia cells by a reactive oxygen species-mediated mechanism. J Biol Chem. 278:37832–37839. 2003. View Article : Google Scholar
27	Li L, Pan S, Zhou X, Meng X, Han X, Ren Y, Yang K and Guan Y: Reduction of in-stent restenosis risk on nickel-free stainless steel by regulating cell apoptosis and cell cycle. PLoS One. 8:e621932013. View Article : Google Scholar : PubMed/NCBI
28	Castello-Branco MVS, Tavares JF, Silva MS, Barbosa Filho JM, Anazetti MC, Frungillo L, Haun M, Melo Diniz MF and Melo PS: Xylodiol from Xylopia langsdorfiana induces apoptosis in HL60 cells. Revista Brasileira de Farmacognosia. 21:1035–1042. 2011.
29	Nahata A, Saxena A, Suri N, Saxena AK and Dixit VK: Sphaeranthus indicus induces apoptosis through mitochondrial-dependent pathway in HL-60 cells and exerts cytotoxic potential on several human cancer cell lines. Integr Cancer Ther. 12:236–247. 2013. View Article : Google Scholar
30	Liu S, Wang XJ, Liu Y and Cui YF: PI3K/AKT/mTOR signaling is involved in (−)-epigallocatechin-3-gallate-induced apoptosis of human pancreatic carcinoma cells. Am J Chin Med. 41:629–642. 2013.